The prognostic value of BCL-2 expression, solely and combined with Ki-67 expression, was determined in prostate cancer patients followed expectantly. Furthermore, associations with well established prognostic markers were tested. Formalin ®xed, paraf®n-embedded tumour tissue obtained at diagnosis was immunohistochemically investigated in 221 patients with a 15 y median followup time. BCL-2 protein was expressed in 114 (52%) tumours and was signi®cantly associated with tumour stage (P 0.01). The prognostic value of BCL-2 expression was signi®cant, using both disease-speci®c (P 0.0015) and overall survival (P 0.005) as endpoint. Patients with a combined BCL-2 negative/Ki-67`low' tumour had the most favourable prognosis. This combined BCL-2/Ki-67 variable was of independently prognostic value in both the entire population (P 0.0001) and in the clinically localized subpopulation (P 0.035).
Introduction
Prostate cancer is the second most commonly diagnosed non-skin cancer disease in Danish males and the second leading cause of cancer death in the same population. 1, 2 Although prostate cancer has been regarded as a slowgrowing, not very aggressive tumour, it is well known that some tumours have an aggressive feature. 3, 4 Therefore, there exists an urgent need to identify prognostic markers that can predict with reasonable accuracy the rate of progression of a prostate cancer as well as the response to particular interventions.
The net tumour growth rate is determined by the balance between the concurrently occurring cell proliferation and cell death in tumour cell populations. 5 The tumour cell proliferation rate can be determined by the mouse monoclonal antibody MIB-1, which is directed against recombinant parts of the Ki-67 antigen present in the G1-, S-, G2-and M-phases of the cell cycle. 6 The prognostic value of tumour cell proliferation rate (Ki-67) has been demonstrated in several previous studies.
7±12
Apoptosis, the genetically programmed mode of cellular suicide, which culminates in nuclear fragmentation and cell death, maintain tissue homeostasis. 13 Abnormalities in the level of apoptosis, allowing the survival of mutated cells, can lead to clonal expansion of preneoplastic cells. 14 BCL-2 is an inner mitochondrial membrane protein, which main effect is to prolong cell survival by avoidance of apoptosis 15, 16 BCL-2 is normally expressed in a variety of cell types, including neurons, memory lymphocytes cells, as well as the regenerating stem cells that line the basement membrane in glandular epithelium in for example the prostate. 17 Furthermore, BCL-2 expression has been observed in a variety of human cancers.
18±24
The aim of this study was to determine the prognostic value of immunohistochemical BCL-2 expression solely and in combination with Ki-67 in prostate cancer patients subjected to watchful waiting. Moreover, associations between BCL-2 expression and well established prognostic markers were tested.
Materials and methods

Patients
In a ®ve year period (01.01.79±31.12.83), 719 residents in Aarhus County, Denmark, made up the total number of men diagnosed with prostate cancer. The patients were identi®ed by the Danish Cancer Registry and retrospectively followed from the time of diagnosis until death. Information on the exact date and cause of death originated from death certi®cates and hospital charts. The retrospectively restaging of the T-and M-classi®cations (UICC 1992) have previously been described in details. 4 The original histopathological grade (WHO 1980) was used. The patients were followed expectantly and palliated at symptoms only. Consequently, 108 (49%) patients with advanced and/or metastatic disease were treated by either bilateral orchiectomy or administration of oestrogen. Detailed accounts of this cancer population has been published previously. 4, 25 Exclusion of patients diagnosed at autopsy, patients without prostate surgery at diagnosis, and patients with incomplete data registration made archival tumour tissue theoretically available in 280 of the patients. Unfortunately, tumour tissue in an additional 59 cases was lost. 4 
Specimens
The sections for the immunostaining procedures were retrieved from the formalin ®xed, paraf®n-embedded tissue used for the original histopathological grading after transurethral resection or prostatectomy in previously untreated patients. The tissue was storaged as paraf®n blocks since operation, and to avoid loss of antigen immunoreactivity, 26 the sections were not stored unstained on glass slides. One representative section per patient was chosen.
Immunohistochemistry
After deparaf®nization in four 4-minute changes of petroleum, the sections were rehydrated through graded ethanol series to distilled water. The sections were then subjected to antigen retrieval by heating the slides in three 5-minute periods in a microwave oven at 650 W in citrate buffer (10 mM; pH 6) with replacement of evaporated buffer between periods of heating. Endogenous peroxidase activity in the tissue sections was blocked with 35% hydrogen peroxide in distilled water (1 : 20) for 20 min.
The primary monoclonal antibody reacting against the BCL-2 protein (clone 124, code no. M0887, IgG1, kappa, Dako, Denmark) was applied to the sections overnight at 4 C at a 1 : 100 dilution in Tris PBS supplemented with 1% BSA.
Immunohistochemistry, against the Ki-67 antigen, was performed using a monoclonal MIB-1 antibody (DIA-NOVA, no. dia 505, clone MIB-1, mouse IgG1, 1 : 100) for 30 min at room temperature. 7, 27 Immunostaining was carried out by use of the Streptavidin-biotin-peroxidase enzyme complex (Dako StreptABComplex/ HRP Duet, Mouse/Rabbit, Code no. K0492), and the chromogen used was Carbazol (Sigma A-5754). Finally the sections were lightly counterstained with 50% haematoxylin.
The positive control sections were cut from normal human tonsil. Furthermore, normal basal cells and lymphocytes in the sections acted as a BCL-2 positive internal control. The negative control sections were performed by substituting the primary antibody with non-speci®c mouse IgG (Dako, Denmark, code no. X 0931).
Quantitation
The distribution of both BCL-2 and Ki-67 immunoreactivity were heterogeneous and there existed a broad variation in staining intensity. Therefore, areas of highest immunoreactivity (`hot spots') were identi®ed by scanning the tumour sections at low magni®cation ( 6 40 and 6 100). Tumour cell counts were performed by random sampling technique at 400 6 using a 10 6 10 grid (0.0625 square mm) in the eye-piece. The blinded procedures were done by a single observer (MB) unaware of the clinical outcome.
BCL-2 staining was considered positive if unequivocal red staining was seen in the tumour cell cytoplasm, and the immunoreactivity was scored semi-quantitatively as the immunoreactive percent of cells a`hot spot': 0±4 (0 no immunoreactivity, 1 approximately 1±25%, 2 approximately 26±50%, 3 approximately 51± 75%, 4 approximately 76±100%). Correspondingly, the intensity of the BCL-2 immunoreactivity was categorized from 0 to 3 compared with the intensity of the lymphocytes (0 no positive staining, 1 weak intensity, 2 moderate intensity, 3 strong intensity).
The Ki-67 score represented the number of stained tumour cell nuclei expressed as a percentage of the total number of at least 500 tumour cell nuclei counted insidè hot spot' areas. 7 The intraobserver and the interobserver variability of the quantitation method described were tested in a previous study 26 concerning tumour cell proliferation in 45 prostate cancer patients, showing that the correlation coef®cients were respectively 0.94 (P`0.001) and 0.91 (P`0.001). In the same study the intertumoural variability was demonstrated signi®cantly higher than the intratumoural variability (P`0.001) by two independent observers. 27 
Statistics
Statistical analysis was performed using the SPSS 6.1 for Windows (SPSS Inc., Chicago, IL) program package. The two-sided chi-square test was used to test for an association between categorical data. Survival functions were calculated according to the method of Kaplan and Meier and the differences between the survival curves were tested by the log rank test. The Cox proportional hazards regression model was used to analyse the prognostic value of the clinical and laboratory characteristics determined at the time of diagnosis. Disease-speci®c death (all deaths caused directly by prostate cancer excluding deaths from coexisting disease, accidents and unknown causes) and overall death were used as endpoints. Twosided P-values less than 0.05 were considered statistically signi®cant.
Results
Patients
The median age at diagnosis was 75 y (range 49±95 y). Only 6 (2%) patients were still alive at the end of the registration period, and according to the hospital charts and death certi®cates 125 (57%) patients died from prostate cancer, while 90 (41%) patients died from other causes. One-hundred and twenty-®ve (57%) patients were diagnosed with clinically localized (T1-2, Nx, M0) disease. Table 1 compares the clinicopathological characteristics at diagnosis of the original 719 patients and the present subpopulation.
BCL-2 expression
The tumours expressed BCL-2 protein in 114 (52%) patients (Table 1 ). In 13 cases the tumour immunoreactivity were categorized as 1 , 10 cancers as 2 , 22 cancers as 3 , while 69 cancers were categorized as 4 . The staining intensity was scored as 1 in 73 tumours, 2 and 3 in 29 and 12 tumours respectively. However, neither the differentiation of positive BCL-2 expression (1±4 ) nor staining intensity (1±3 ) provided additional information to that already given by a simple separation of the tumours as being BCL-2 expressing positive or negative. Consequently, in the following text BCL-2 refers to negative or positive expression only.
BCL-2 expression was signi®cantly associated with Tclassi®cation (P 0.03) and tumour stage (clinically localized versus clinically advanced; P 0.01), while no such association with either M-classi®cation (P 0.2) or histopathological grade (P 0.8) was found. The proliferation rate expressed by the Ki-67 score was categorized as`low' or`high' by the median Ki-67 value: total population: 10.3% (range 0 ± 46.1%); clinically localized patients: 8.2% (range 0±27.9%). 7 As shown in Table 1 , no signi®cant association between BCL-2 expression and tumour cell proliferation (`low' vs`high'; P 0.09) existed.
Patients diagnosed with BCL-2 expressing tumours had a signi®cantly shorter disease-speci®c (P 0.0015; Figure 1 ) as well as overall survival (P 0.005) compared to patients with BCL-2 negative tumours. However, focusing solely at the 125 clinically localized cancer patients signi®cance was not achieved (P 0.15).
BCL-2 expression and tumour proliferation
The Kaplan±Meier plots in Figure 2 illustrate the signi®-cant (P`0.0001) prognostic advantage of the 60 (27%) patients harboring a combined BCL-2 negative/slowly proliferating (Ki-67`low') tumour compared to the patients suffering from BCL-2 expressing and/or highly proliferating tumours. The classic prognostic markers in the four different BCL-2/Ki-67 groups were compared in Table 2 . BCL-2 expression, as an isolated variable, was not a prognostic marker in clinically localized cancer, however, the combined BCL-2 negative/Ki-67`low' tumour patients had a signi®cantly (0.035) longer disease-speci®c survival than patients suffering from other BCL-2/Ki-67 tumour combinations (Figure 3 ). Table 3 presents 4 Cox multivariable regression analyses including (A) classic prognostic markers, BCL-2 and Ki-67 expression, while the four different BCL-2/Ki-67 combinations were additionally included in the B analyses. The combined BCL-2 negative/Ki-67`low' variable (P 0.0001), T-classi®cation (P`0.0001) and histopathological grade (P 0.03) were all independent prognostic markers in the entire population using disease-speci®c death as endpoint. However, the combined BCL-2 negative/Ki-67 low' variable was the only one reaching signi®cance (P 0.0003) in the clinically localized subpopulation. Immunohistochemical BCL-2 and Ki-67 expression M Boore et al 
Multivariable analyses
Discussion
The current results were based on a subpopulation originating from a previously described complete prostate cancer population with a nearly complete follow-up subjected to watchful waiting. 4 This population consists of relatively elderly (median age, 75 y) and often symptomatic prostate cancer patients compared to patients detected in the PSA era. However, the conservative therapeutic approach towards these patients makes the prognosis information of patients with favourable marker status important. Thereby retrospectively obtained information can be very valuable, although, the clinical information is often incomplete and patients at risk of being understaged. Naturally, retrospective tumour staging is problematic especially with regard to Table 2 Clinicopathological characteristics compared with four different BCL-2/Ki-67 expression combinations at diagnosis in 221 prostate cancer patients BCL2-/Ki-67 low BCL2 /Ki-67 low BCL2-Ki-67 high Figure 3 Combined BCL-2 and Ki-67 expression at diagnosis in 125 clinically localized prostate cancer patients correlated with disease-speci®c survival. Ki-67:`low'`median score (8.2%);`high' b median score.
Immunohistochemical BCL-2 and Ki-67 expression M Boore et al a disease with no therapeutic consequences of the accuracy in TM staging. Although the tumour tissue used for immunohistochemical analyses is relatively old the Ki-67 antigenicity has been shown to be preserved in to previous studies. 7, 27 Moreover normal basal cells and lymphocytes acted as internal positive controls for BCL-2 immunoreactivity. The heterogeneity of prostate cancer is a well established fact, 28, 29 and as expected we observed a heterogeneous distribution of cytoplasmatic BCL-2 immunoreactivity with a variable intensity. For that reason both BCL-2 expression and proliferative rate were quantitated in immunoreactivity`hot spot' areas of the tumours. In accordance with previous studies examining tumours of various stages 30, 31 our results showed that approximately half of the tumours expressed BCL-2 protein. In general, BCL-2 has been found to be expressed in at most one out of four clinically localized tumours. 32±34 The relatively high number (48%) of clinically localized BCL-2 expressing tumours in the current study might partly be explained by understaging as well as different limits for positive BCL-2 quantitation among different studies.
As in the current study, an association between BCL-2 expression and clinical stage has previously been demonstrated, 32±35 while in other studies no such association was found. 30, 31 Moreover, studies of BCL-2 expression in relation to histopathological grade have also been characterized by con¯icting results. In accordance with several previous studies, 30,33,36±39 but in contrast to others, 31, 32, 34, 35, 40 we found no association between BCL-2 expression and histopathological grade (P 0.8; Table  1 ). Thereby, our result supports the suggestion of BCL-2 expression and histopathological grade being two independent prognostic markers in prostate cancer disease. 37 We showed, that BCL-2 expression as a univariable marker was signi®cantly correlated with disease-speci®c survival in a prostate cancer population of various stages treated without intention to cure (Figure 1) . Although, previous studies most frequently have concerned patients subjected to theoretically curable treatment, similar correlations have been demonstrated by others. 32, 33, 35 However, Stattin et al 31 only experienced a slight and insigni®cant association between longer cancer-speci®c survival and low BCL-2 index in 150 untreated prostate cancer patients. In accordance with some previous studies 33, 35 our multivariable analyses demonstrated an insigni®cant prognostic value of BCL-2 expression in both the entire population (P 0.1) and the clinically localized subpopulation (P 0.2).
It is generally accepted that net tumour growth is characterized by a balance between cell proliferation and cell loss rate, 5 and in a previous study we have demonstrated the signi®cant prognostic relevance of tumour cell proliferation (Ki-67) in the current prostate cancer population. 7 A transition of late stage high-grade prostatic intraepithelial neoplastic cells into localized prostate cancer cells has been shown not to involve any further increase in proliferation but a decrease in death. 41 In accordance with Bubendorf et al 33 the current results showed no signi®cant association between BCL-2 expression and tumour cell proliferation (P 0.09) supporting the suggestion, that alterations leading to an increased cell proliferation may be independent from mechanisms affecting the control of programmed cell death. Moreover, like in the Swiss study, 33 the present individuals suffering from a combined BCL-2 negative and slowly proliferative tumours (Ki-67`low') had a signi®cantly better prognosis than patients with BCL-2 expressing and/or high growth fraction tumours (Figure 2 and 3) . This result suggests, that the ability to resist apoptosis does not offer an advantage to rapidly proliferating tumours exclusively, but to tumours characterized by a low proliferation rate as well. Conclusions BCL-2 expression was signi®cantly associated with clinical stage, and patients diagnosed with a BCL-2 expressing tumour had a signi®cantly poorer prognosis than BCL-2 negative tumour patients subjected to watchful waiting. Patients with combined BCL-2 negative/Ki-67 low' tumours had a relatively favorable prognosis, and this BCL-2/Ki-67 expression combination demonstrated an independently prognostic value in both the entire population as well as the clinically localized and theoretically curable subpopulation.
